Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our
treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
Hong Kong LEmed, the specialist stem cell and laser therapy research and distribution group, announced today that it is supporting ALS research which uses Adult Stem Cells, the only stems cells to successfully complete clinical trials for incurable diseases.
Wan Chai, Hong Kong, September 15, 2014 -- Hong Kong LEmed (Leading Edge Medical Ltd.), the specialist stem cell and laser therapy research and distribution group, announced today that it is supporting ALS research which uses Adult Stem Cells, the only stems cells to successfully complete clinical trials for incurable diseases.
In view of the enormous amount of attention the ice bucket challenge has brought to ALS (Amyotrophic Lateral Sclerosis) often referred to as Lou Gehrig's Disease, LEmed is excited to be at the forefront of the revolutionary stem cell treatment technology used to fight this horrific disease.
Considering the fact that no effective long-term treatment exists for patients with ALS as well as a long list of neuro-inflammatory and neuro-degenerative disorders, LEmed has encouraged one of its lead doctors, Professor Shimon Slavin of Tel Aviv, to press forward with his adult stem cell technology.
Dr. Slavin is one of the only stem cell MD's in the world who has been successfully treating no-hope patients with a large variety of life threatening malignant and non-malignant indications for more than 20 years. The current research efforts in Tel Aviv is directed towards developing new approaches for regenerative medicine focusing on the use of multi-potent mesenchymal stromal cells (MSC) derived from either bone marrow or fat tissue (the patient own cells), or using unrelated placenta & cord tissue MSCs, derived from healthy newborn babies.
He has documented how, using new innovative technologies, that MSCs from all sources can be targeted to any part of the central nervous system by a non-invasive extra corporeal technology based on the use of low energy acoustic shockwave therapy. In parallel, they attempt to activate undifferentiated MSCs by multi-channel low energy laser light therapy, all of which are theoretically potentially beneficial to ALS patients and most likely to other indications of neuro-inflammatory and neuro-degenerative disorders.
The future goal is to use differentiated MSCs, both autologous and readily available allogeneic off-the-shelf, using differentiated placenta & cord tissue derived MSCs that were also shown to secrete neurotrophic factors that may help regulate the function of neurons in the brain and also play an important role in repairing or replacing damaged neurons. Such factors may also be therapeutically effective by activation of locally residing multi-potent stem cells located throughout the central nervous system, which otherwise do not respond to the body need.
LEmed strongly recommends supporting these research efforts that are the most promising by an experienced team that has already treated several hundreds of patients with ALS and a variety of other neuro-degenerative disorders and autoimmune diseases, thus far with undifferentiated MSCs. Clinical application of the next generation of cellular therapy depends on additional research to confirm the advantage of targeted, activated and also differentiated MSCs in comparison with current therapeutic approach based on the use of undifferentiated MSCs enriched in vitro. Considering the genetic background of patients with familial type ALS and more subtle molecular abnormalities even in patients considered as sporadic ALS, and the practical need to have available readily available cells for treatment of patients with rapidly progressive disease, much attention will be given in the future to the use of young and normal MSCs derived from placenta & cord tissue of normal newborn babies of consenting mothers
Donations should be addressed to CordCure Ltd in Tel Aviv, Israel, earmarked for ALS Research.
Account Name: CordCure
Bank Poalim Main Branch # 170 50 Rothchild Street Tel Aviv 61000
Account # 170-223405 Swift: POALILIT IBAN: IL880121700000000223405
About Leading Edge Medical Ltd.:
Cellular medicine is revolutionizing medical treatment in the 21st century and Leading Edge Medical's treatments are at the forefront of the field. Thousands of patients around the world have already benefited from bio-technologies using stem cells and intravenous laser therapy. Diseases once considered incurable are responding well to stem cell therapies and are restoring a quality of life to patients they thought they had lost forever.
LEmed is committed to applying modern day best practices to the growing field of regenerative medicine. With advanced medical treatment facilities offering personalized, ongoing care plans and the highest quality of customer service, we are dedicated to providing a better life for patients.
Contact:
Jeffery Tobin
Leading Edge Medical, Ltd
14F, 8 Hennessy Road
China Hong Kong Tower
Wan Chai, Hong Kong 999077
+852 21270684
info@healingmed.com
http://www.healingmed.com